This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Surging Earnings Estimates Signal Upside for AMN Healthcare (AMN) Stock
by Zacks Equity Research
AMN Healthcare (AMN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
LabCorp (LH) to Enhance Access to OmniSeq INSIGHT via New Program
by Zacks Equity Research
LabCorp's (LH) new sponsored lung cancer program will expand access to comprehensive genomic testing for NSCLC patients to guide informed treatment decisions.
Cooper Companies (COO) Q2 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
Despite a decline in the bottom line, Cooper Companies' (COO) fiscal second-quarter earnings reflect solid segmental performance.
Phibro (PAHC) Business Hurt by Macro Issues, FX Fluctuations
by Zacks Equity Research
The increase in raw material costs and freight costs continues to pose challenges for Phibro (PAHC).
Accuray's (ARAY) New Tie-Up to Augment Treatment Planning
by Zacks Equity Research
Accuray (ARAY) partners with Limbus AI to enhance the treatment planning process and patient care.
Leverage Relative Price Strength With These 5 Top Stocks
by Nilanjan Choudhury
Kronos Worldwide (KRO), Ulta Beauty (ULTA), AMN Healthcare Services (AMN), Marathon Petroleum (MPC) and Sanderson Farms (SAFM) are five stocks with explosive relative price strength.
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell's (OMCL) better-than-expected results and new launches.
Veeva Systems (VEEV) Beats on Q1 Earnings, Ups FY23 View
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performances by both of its segments.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
DexCom (DXCM) to Boost Diabetes Management With New Coverage
by Zacks Equity Research
DexCom's (DXCM) G6 CGM System gets public coverage through Prince Edward Island's Diabetes Glucose Sensor Program, which can aid in effective diabetes management.
Abbott (ABT) Receives FDA Nod for FreeStyle Libre 3 System
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre 3 system offers greater accuracy and easier application compared with other CGMs.
Here's Why Investors Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) better-than-expected results and strong performance across several geographies.
Here's Why You Should Retain QuidelOrtho (QDEL) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
Here's Why Investors Should Retain Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) continues to gain traction from its robust strategic deals. However, stiff competition remains a woe.
Stryker's (SYK) Q Guidance System Receives FDA Approval
by Zacks Equity Research
Stryker's (SYK) Q Guidance System is expected to be a procedural ecosystem for surgeons during image-guided surgery following the receipt of the FDA approval.
Thermo Fisher (TMO) North America Sales Grow, Margin Woe Stays
by Zacks Equity Research
Thermo Fisher (TMO) witnesses core business strength across segments, end markets, and geographies.
Reasons to Retain Integer Holdings (ITGR) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and solid foothold in the broader MedTech space.
Factors that Make UnitedHealth Group (UNH) an Attractive Bet Now
by Zacks Equity Research
UnitedHealth Group (UNH) continues to benefit from sustained top-line growth, a growing membership, and a strong cash position.
Here's Why Investors Should Retain Illumina (ILMN) Stock Now
by Zacks Equity Research
Investors are optimistic about Illumina's (ILMN) better-than-expected results and revenue contributions from the GRAIL business.
Wall Street Analysts See a 44% Upside in AMN Healthcare (AMN): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 43.7% in AMN Healthcare (AMN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Zacks.com featured highlights include Tecnoglass, AMN Healthcare Services, Cumulus Media, and Universal Logistics Holdings
by Zacks Equity Research
Tecnoglass, AMN Healthcare Services, Cumulus Media, and Universal Logistics Holdings are part of Screen of the Week article.
Tandem Diabetes (TNDM) Pump Shipment Recovers, Price Issue Ails
by Zacks Equity Research
Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.
Integra (IART) Gains From Innovation Amid Cost Constraints
by Zacks Equity Research
Integra's (IART) international sales in CSS grow led by the strong performance of CereLink in Europe and growth in Asia.
AMN Healthcare (AMN) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
AMN Healthcare (AMN) is well positioned to outperform the market, as it exhibits above-average growth in financials.